Literature DB >> 16418806

Induction of pathogenic anti-dsDNA antibodies is controlled on the level of B cells in a non-lupus prone mouse strain.

Dirk Langnickel1, Philipp Enghard, Claudia Klein, Reinmar Undeutsch, Berthold Hocher, R Manz, G R Burmester, Gabriela Riemekasten.   

Abstract

The SmD1(83-119) peptide is a main target of autoantibodies and T cells in human and murine lupus, but its role in autoimmunity induction remains elusive. Therefore, female Balb/c mice and (NZW x Balb/c)F1 [CWF1] mice with identical MHC haplotype as lupus prone NZB/W mice were immunized with SmD1(83-119). Immunizations of CWF1 mice with SmD1(83-119), but not with the controls (irrelevant peptide, HEL peptide, or saline), induced anti-SmD1(83-119) and anti-dsDNA antibodies and proteinuria not present in Balb/c mice. DsDNA-specific plasma cell induction after SmD1(83-119) immunizations was confirmed by ELISPOT assays showing that the generation of dsDNA-specific antibody forming cells (AFC) was mainly driven by increased T-cell help. T-cell help for the generation of dsDNA-specific AFC was also present in saline-treated CWF1 mice but was controlled on the levels of B cells preventing autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16418806     DOI: 10.1007/s10875-006-8904-y

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  37 in total

1.  Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry.

Authors:  Micah T McClain; Latisha D Heinlen; Gregory J Dennis; Jon Roebuck; John B Harley; Judith A James
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

2.  Strong acceleration of murine lupus by injection of the SmD1(83-119) peptide.

Authors:  G Riemekasten; A Kawald; C Weiss; A Meine; J Marell; R Klein; B Hocher; C Meisel; G Hausdorf; R Manz; T Kamradt; G R Burmester; F Hiepe
Journal:  Arthritis Rheum       Date:  2001-10

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Lupus humoral autoimmunity after short peptide immunization.

Authors:  J A James; R H Scofield; J B Harley
Journal:  Ann N Y Acad Sci       Date:  1997-04-05       Impact factor: 5.691

5.  Systemic lupus erythematosus induced by Epstein-Barr virus infection.

Authors:  R Verdolini; L Bugatti; M Giangiacomi; M Nicolini; G Filosa; R Cerio
Journal:  Br J Dermatol       Date:  2002-05       Impact factor: 9.302

Review 6.  Role of apoptosis in autoimmunity.

Authors:  H M Lorenz; M Herrmann; T Winkler; U Gaipl; J R Kalden
Journal:  Apoptosis       Date:  2000-11       Impact factor: 4.677

7.  T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus.

Authors:  G Riemekasten; C Weiss; S Schneider; A Thiel; A Bruns; F Schumann; S Bläss; G-R Burmester; F Hiepe
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

8.  Overlap of the anti-Sm and anti-DNA responses of MRL/Mp-lpr/lpr mice.

Authors:  D D Bloom; J L Davignon; P L Cohen; R A Eisenberg; S H Clarke
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

9.  Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood.

Authors:  Uk Yeol Moon; Su Jin Park; Sang Taek Oh; Wan-Uk Kim; Sung-Hwan Park; Sang-Heon Lee; Chul-Soo Cho; Ho-Youn Kim; Won-Keun Lee; Suk Kyeong Lee
Journal:  Arthritis Res Ther       Date:  2004-05-07       Impact factor: 5.156

10.  B cells solicit their own help from T cells.

Authors:  B Stockinger; T Zal; A Zal; D Gray
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  1 in total

1.  Anti-nuclear antibody production and autoimmunity in transgenic mice that overexpress the transcription factor Bright.

Authors:  Malini Shankar; Jamee C Nixon; Shannon Maier; Jennifer Workman; A Darise Farris; Carol F Webb
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.